Chronic Kidney Disease (CKD): Diagnosis and Management

Written by Dr. Muhammad Salar Raza · Manually reviewed by Dr. Muhammad Salar Raza · Content updated

Clinical Pathway

Define CKD as reduced eGFR below 60 mL/min/1.73 m2 or markers of kidney damage such as albuminuria persisting beyond 3 months, and stage it by eGFR and albuminuria category. Control blood pressure, targeting roughly below 130/80 mmHg, using an ACE inhibitor or ARB when albuminuria is present. Add an SGLT2 inhibitor for diabetic CKD with albuminuria, prescribe a statin for cardiovascular risk, and adjust doses of renally cleared drugs. Avoid nephrotoxins including NSAIDs and unchecked contrast exposure. Refer to nephrology when eGFR falls below 30, declines rapidly, or when refractory hyperkalemia, acidosis, or anemia emerges, and vaccinate against hepatitis B, influenza, and pneumococcus.

Clinical Reasoning

Staging with both eGFR and albuminuria predicts progression far better than creatinine alone; heavy albuminuria at any eGFR is high risk. ACE inhibitors and ARBs reduce intraglomerular pressure and albuminuria, so an early modest creatinine rise of up to 30% after initiation is expected and is not a reason to stop. Metformin is safe down to eGFR 30 with dose adjustment but should be withheld below that. The practical exam trap is the patient with stable stage 3 CKD: the correct action is risk-factor management and monitoring, not dialysis referral, while missed red flags such as rapidly falling eGFR or new anemia warrant specialist review.

Sample MCQ

A 60-year-old man with type 2 diabetes has an eGFR of 45 mL/min/1.73 m2 and a urine albumin-creatinine ratio of 320 mg/g, stable over 6 months. Blood pressure is 142/86 mmHg. Which medication most directly slows progression of his kidney disease?

  • ALisinopril
  • BNaproxen for his knee pain
  • CFurosemide
  • DNo medication, monitoring only

Correct Answer: Lisinopril

Diabetic CKD with albuminuria is the classic indication for an ACE inhibitor such as lisinopril, which lowers intraglomerular pressure, reduces albuminuria, and slows eGFR decline independent of its blood pressure effect. Naproxen and other NSAIDs constrict the afferent arteriole and accelerate kidney injury, so they should be avoided. Furosemide treats fluid overload but does not modify progression and is not first-line for hypertension in CKD. Monitoring alone undertreats a patient with confirmed albuminuric CKD; renin-angiotensin blockade, blood pressure control, and typically an SGLT2 inhibitor and statin are the standard.

Guidelines and further reading

Deep Dive Walkthroughs

Read full case walkthroughs with option-by-option analysis for this topic:

Related Clinical Topics

Nephrolithiasis (Kidney Stones): Evaluation and Management

Nephrolithiasis typically presents with acute, severe, colicky flank pain that may radiate to the groin, often accompanied by hematuria, nausea, and vomiting. The gold standard imaging modality for diagnosing kidney stones is a non-contrast CT scan of the abdomen and pelvis. It offers high sensitivity and specificity for detecting stones, determining their size and location, and identifying associated complications like hydronephrosis. Initial management focuses on pain control (NSAIDs or opioids) and hydration. Stones smaller than 5mm often pass spontaneously.

Urosepsis: Diagnosis and Management

Urosepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection originating from the urinary tract. It represents a severe systemic inflammatory response syndrome (SIRS) triggered by a urinary tract infection (UTI). Treatment involves immediate initiation of broad-spectrum intravenous antibiotics, empirically selected to cover common uropathogens, and subsequently narrowed based on culture sensitivities. Aggressive supportive care, including intravenous fluid resuscitation to correct hypotension, and vasopressors if needed, is crucial to maintain organ perfusion. Source control, such as removal of an obstructed catheter or drainage of a collection, is also a critical component of management. Patients commonly present with signs of systemic infection, including high fever, chills, tachycardia, and hypotension. They may also exhibit symptoms related to the urinary source, such as dysuria, flank pain, urgency, or suprapubic tenderness. Signs of organ dysfunction like altered mental status, oliguria, tachypnea, or mottled skin may also be present, indicating severe sepsis or septic shock.

Systemic Lupus Erythematosus (SLE): Diagnosis and Management

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by widespread inflammation and tissue damage, as the immune system mistakenly attacks its own healthy tissues and organs. It can affect nearly any part of the body, including joints, skin, kidneys, brain, heart, and lungs. Treatment for SLE aims to control symptoms, reduce inflammation, prevent organ damage, and minimize flare-ups. This typically involves corticosteroids for acute flares, antimalarials (e.g., hydroxychloroquine) for long-term disease control, and immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate mofetil) for moderate to severe disease. Biologic agents (e.g., belimumab, anifrolumab) are also used for targeted immunomodulation. SLE presents with a diverse range of symptoms due to multi-organ involvement. Common manifestations include joint pain and swelling (arthritis/arthralgia), a characteristic butterfly-shaped malar rash, photosensitivity, oral ulcers, and profound fatigue. More severe features can include lupus nephritis (kidney inflammation), neurological issues (seizures, psychosis), serositis (inflammation of lining of lungs or heart), and hematologic abnormalities (anemia, leukopenia, thrombocytopenia).

SMLE Preparation Resources

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks